Cargando…

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

BACKGROUND: New treatments are needed to reduce the risk of progression of coronavirus disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: We conducted a phase 3, double-blind...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jayk Bernal, Angélica, Gomes da Silva, Monica M., Musungaie, Dany B., Kovalchuk, Evgeniy, Gonzalez, Antonio, Delos Reyes, Virginia, Martín-Quirós, Alejandro, Caraco, Yoseph, Williams-Diaz, Angela, Brown, Michelle L., Du, Jiejun, Pedley, Alison, Assaid, Christopher, Strizki, Julie, Grobler, Jay A., Shamsuddin, Hala H., Tipping, Robert, Wan, Hong, Paschke, Amanda, Butterton, Joan R., Johnson, Matthew G., De Anda, Carisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Massachusetts Medical Society 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693688/ https://www.ncbi.nlm.nih.gov/pubmed/34914868 http://dx.doi.org/10.1056/NEJMoa2116044

Ejemplares similares

Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial
por: Johnson, Matthew G., et al.
Publicado: (2023)

511. Treatment with Molnupiravir in the MOVe-In and MOVe-Out Clinical Trials Results in an Increase in Transition Mutations Across the SARS-CoV-2 Genome
por: Strizki, Julie, et al.
Publicado: (2021)

543. Molnupiravir Maintains Antiviral Activity Against SARS-CoV-2 Variants In Vitro and in Early Clinical Studies
por: Grobler, Jay, et al.
Publicado: (2021)

153. Molnupiravir Exhibits a High Barrier to the Development of SARS-CoV-2 Resistance in vitro
por: Strizki, Julie, et al.
Publicado: (2022)

Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel
por: Weil, Clara, et al.
Publicado: (2023)

Letter to the Editor in Response to Zhou et al
por: Troth, Sean, et al.
Publicado: (2021)

Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial
por: Guan, Yanfen, et al.
Publicado: (2023)

1574. Multivariate Regression Analysis to Determine Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Trial
por: Tipping, Robert, et al.
Publicado: (2020)

Immunology of Nonhospital and Intrahospital Infections
por: Zemskov, V. M., et al.
Publicado: (2021)

1460. Imipenem/Cilastatin (IMI)/Relebactam (REL) in Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia (HABP/VABP): Subgroup Analyses of Critically Ill Patients in the RESTORE-IMI 2 Trial
por: Chen, Luke F, et al.
Publicado: (2020)

Evaluation of Adrenal Function in Nonhospitalized Patients with Cirrhosis
por: Moini, Maryam, et al.
Publicado: (2017)

1339. Results for the Supplemental Microbiological Modified Intent-to-Treat (SmMITT) Population of the RESTORE-IMI 1 Trial of Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients with Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Kaye, Keith, et al.
Publicado: (2018)

1230. Clinical and Microbiologic Outcomes by Causative Pathogen in Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Treated with Imipenem/Cilastatin (IMI)/Relebactam (REL) Versus Piperacillin/Tazobactam (PIP/TAZ)
por: Losada, Maria C, et al.
Publicado: (2020)

Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong
por: Lui, David T. W., et al.
Publicado: (2023)

Colonoscopy quality in community hospitals and nonhospital facilities in Korea
por: Lee, Jae Gon, et al.
Publicado: (2021)

Thromboprophylaxis in hospitalized and nonhospitalized medical patients: what’s new?
por: Rezende, Suely M., et al.
Publicado: (2023)

1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Brown, Michelle, et al.
Publicado: (2018)

Neurologic manifestations of nonhospitalized patients with COVID‐19 in Wuhan, China
por: Ding, Hong, et al.
Publicado: (2020)

Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19
por: Chhiba, Krishan D., et al.
Publicado: (2020)

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
por: Hammond, Jennifer, et al.
Publicado: (2022)

Assessment of the Risk of Venous Thromboembolism in Nonhospitalized Patients With COVID-19
por: Fang, Margaret C., et al.
Publicado: (2023)

Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)

Computational Analysis of Molnupiravir
por: Sharov, Artem V., et al.
Publicado: (2022)

Molnupiravir for COVID-19
Publicado: (2022)

Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study
por: Brown, Michelle L, et al.
Publicado: (2020)

Use of donor human milk in nonhospitalized infants: An infant growth study
por: Bramer, Solange, et al.
Publicado: (2021)

Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19
por: Martin, David E., et al.
Publicado: (2023)

Ocular Symptoms among Nonhospitalized Patients Who Underwent COVID-19 Testing
por: Gangaputra, Sapna S., et al.
Publicado: (2020)

Olfactory and Gustatory Outcomes in COVID-19: A Prospective Evaluation in Nonhospitalized Subjects
por: Paderno, Alberto, et al.
Publicado: (2020)

COVID-19, Vulnerability, and Long-Term Mortality in Hospitalized and Nonhospitalized Older Persons
por: Di Bari, Mauro, et al.
Publicado: (2022)

Prevalence, molecular characteristics and antimicrobial susceptibility patterns of MRSA in hospitalized and nonhospitalized patients in Barbados
por: Gittens-St Hilaire, M.V., et al.
Publicado: (2020)

Symptom Profiles and Progression in Hospitalized and Nonhospitalized Patients with Coronavirus Disease, Colorado, USA, 2020
por: Vahey, Grace M., et al.
Publicado: (2021)

Publisher Correction: Molnupiravir: coding for catastrophe
por: Malone, Brandon, et al.
Publicado: (2021)

Molnupiravir, une affaire franco-européenne
por: Manus, Jean-Marie
Publicado: (2021)

Molnupiravir: From Hope to Epic Fail?
por: Focosi, Daniele
Publicado: (2022)

Why Molnupiravir Fails in Hospitalized Patients
por: Brown, Ashley N., et al.
Publicado: (2022)

New symptoms and prevalence of postacute COVID-19 syndrome among nonhospitalized COVID-19 survivors
por: Albtoosh, Asma S., et al.
Publicado: (2022)

Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis
por: Lu, Li-Chin, et al.
Publicado: (2022)

Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19
por: Lim, Sarah, et al.
Publicado: (2022)

Prevalence and Characteristics Associated With Post–COVID-19 Condition Among Nonhospitalized Adolescents and Young Adults
por: Selvakumar, Joel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a9rqqrpth8d517fh0os5cm2c0a